Boehringer Ingelheim Pharma Gmbh & Co Kg

Boehringer Ingelheim Pharma Kg

Boehringer Ingelheim International Gmbh

Dr. Karl Thomae Gmbh

Dr. Karl Thomae Gesellschaft MIT Beschranter Haftung

Eckhart Bauer

Klaus Rudolf

Henri Doods

Stephan Georg Mueller

Alexander Dreyer

Dirk Stenkamp

Philipp Lustenberger

Kai Gerlach

Kirsten Arndt

Marcus Schindler

Wolfgang Eberlein

Wolfhard Engel

Rudolf Hurnaus

Matthias Grauert

Wolfgang Wienen

Matthias Hoffmann

Henning Priepke

Herbert Nar

Roland Pfau

Gerhard Hallermayer

Christoph Hoenke

Georg Dahmann

Stefan Peters

Uwe Joerg Ries

Gerhard Schaenzle

Steffen Breitfelder

Annette Schuler-Metz

Thorsten Lehmann-Lintz

Gunter Trummlitz

Alexander Pautsch

Christian Eickmeier

Sandra Handschuh

Martin Steegmaier

Trixi Brandl

Peter Gruber

Gerald Pohl

Peter Danneberg

James Gillard

Frank Buettner

Norbert Redemann

Gisela Schnapp

Udo Maier

Joachim Kahling

Anne T Joergensen

Jochen Schmid

Jens Jurgen Quant

Frank Kalkbrenner

Horst Lechner

Gerhard Schaenze

Anne Joergensen

Frank Büttner

New compounds of formula 1 are provided which by virtue of their pharmaceutical activity as PI3-kinase modulators may be used in the therapeutic field for the treatment of inflammatory or allergic diseases. Examples of these include inflammatory and allergic respiratory complaints, inflammatory diseases of the gastro-intestinal tract and motor apparatus, inflammatory and allergic skin diseases, inflammatory eye diseases, diseases of the nasal mucosa, inflammatory or allergic conditions involving autoimmune reactions or inflammations of the kidney.

Inhibitors of PI3-kinases

CGRP antagonists of the formula of which the following are exemplary:

CGRP antagonists

The present invention relates to CGRP antagonists of general formula wherein A, U, V, W, X and Rto Rare defined as in claimthe tautomers, diastereomers, enantiomers, hydrates, mixtures thereof and the salts thereof as well as the hydrates of the salts, particularly the physiologically acceptable salts thereof with inorganic or organic acids, pharmaceutical compositions containing these compounds, the use thereof and processes for preparing them.

Selected CGRP antagonists, processes for preparing them and their use as pharmaceutical compositions

The present invention relates to substituted piperidines of general formula wherein R, Rto R, A, X, Z and n are defined as in claim 1, the tautomers, diastereomers, enantiomers, mixtures and salts thereof, particularly the physiologically acceptable salts thereof with inorganic or organic acids or bases which have valuable pharmacological properties, particularly CGRP-antagonistic properties, pharmaceutical compositions containing these compounds, the use thereof and processes for the preparation thereof.

Substituted piperidines, pharmaceutical compositions containing these compounds, their use and processes for the preparation thereof

The present invention relates to new substituted nitrogen-containing heterobicyclic compounds of general formula wherein B, Xto Xand Rto Rare defined as in claimthe tautomers, the enantiomers, the diastereomers, the mixtures thereof and the salts thereof, particularly the physiologically acceptable salts thereof with inorganic or organic acids or bases, which have valuable properties. The compounds of the above general formula I as well as the tautomers, the enantiomers, the diastereomers, the mixtures thereof and the salts thereof, particularly the physiologically acceptable salts thereof with inorganic or organic acids or bases, and their stereoisomers have valuable pharmacological properties, particularly an antithrombotic activity and a factor Xa-inhibiting activity.

Substituted nitrogen-containing heterobicycles, the preparation thereof and their use as pharmaceutical compositions

A compound of general formula (I) wherein R and Rare as defined herein, or a tautomer, diastereomer, enantiomer, or salt thereof, particularly the physiologically acceptable salts thereof, which have valuable pharmacological properties, particularly CGRP-antagonistic properties, pharmaceutical compositions containing the compound, their use, and processes for preparing them.

Cyclopropane CGRP antagonists, medicaments containing these compounds, and method for the production thereof

Substituted carboxylic acid amides of general formula wherein A, B, and Rto Rare as defined herein, and the tautomers and the salts thereof, particularly the physiologically acceptable salts thereof with inorganic or organic acids or bases, which have valuable properties, such as antithrombotic activity and factor Xa-inhibiting activity.

Carboxylic acid amides, the preparation thereof, and their use as pharmaceutical compositions

The present invention relates to compounds of general formulaR&#x2014;Z&#x2014;Z&#x2014;Z&#x2014;R, &#x2003;&#x2003;(I)wherein

Arylalkane, arylalkene and aryl azaalkane, medicaments containing said compounds and method for the production thereof

The present invention relates to substituted piperidines of general formulawherein R, Rto R, A, X, Z and n are defined as in claim 1, the tautomers, diastereomers, enantiomers, mixtures and salts thereof, particularly the physiologically acceptable salts thereof with inorganic or organic acids or bases which have valuable pharmacological properties, particularly CGRP-antagonistic properties, pharmaceutical compositions containing these compounds, the use thereof and processes for the preparation thereof.

The present invention relates to substituted piperidines of general formulawherein

Substituted piperidines, medicaments containing these compounds, and methods for the production thereof

Dihydropteridinones, processes for preparing them and their use as pharmaceutical compositions

Compounds of the formula ##STR1## wherein R.sub.1 is phenyl, halo- and/or methyl-substituted phenyl or pyridinyl;

Vinylogous carboxamides

This invention relates to vehicles for the administration of bromhexine. More specifically, this invention relates to a composition for the delayed release of bromhexine which comprises (i) spheroid particles or tablets comprised of (a) bromhexine and/or acid addition salts thereof and (b) at least one pharmacologically acceptable acid or acidic substance, the total amount of acid substance from acid addition salts present and the acid or acidic substance being in a ratio of at least 2 mols to 1 mol of bromhexine, and (ii) a coating surrounding said spheroid particles or tablets, said coating being comprised of from about 50 to 100 percent by weight of acid-insoluble lacquers soluble in intestinal juices and from about 0 to 50 percent by weight of lacquers insoluble in gastric and intestinal juices and said coating being present in an amount of from about 2 to 30 percent by weight, based upon the weight of the spheroid particles or tablets.

Bromhexine delayed-release pharmaceutical form

Growing community of inventors

Biberach, Germany

Eckhart Bauer